In vivo effects of the cytochrome P-450 suicide substrate 2-isopropyl-4-pentenamide (allylisopropylacetamide) on the disposition and metabolic pattern of propranolol.
D000081:Acetamides / Q000494:pharmacology*; D000502:Allylisopropylacetamide / Q000494:pharmacology*; D000818:Animals; D001711:Biotransformation / Q000187:drug effects; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004285:Dogs; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D007700:Kinetics; D008297:Male; D010634:Phenobarbital / Q000494:pharmacology; D011433:Propranolol / Q000378:metabolism*; D019946:Propylene Glycol; D011409:Propylene Glycols / Q000494:pharmacology
D000081:Acetamides; D065607:Cytochrome P-450 Enzyme Inhibitors; D011409:Propylene Glycols; D000502:Allylisopropylacetamide; D019946:Propylene Glycol; D003577:Cytochrome P-450 Enzyme System; D011433:Propranolol; D010634:Phenobarbital